OverviewSuggest Edit

Spherix develops drugs and supplements, and offers a commercialization platform for protected technologies. It is on a mission to create and grow shareholder value through innovations that benefit its investors. The Company acquires intellectual property from patent holders in order to maximize the value of the patent holdings by conducting and managing a licensing campaign. Its activities generally include the acquisition and development of patents through internal or external research and development. 

TypePublic
Founded1967
HQBethesda, US
Websitespherix.com
Employee Ratings0

Latest Updates

Employees (est.) (Dec 2018)6(+100%)
Revenue (FY, 2018)$28 K(-97%)
Share Price (May 2019)$3.2 (+10%)

Spherix Office Locations

Spherix has an office in Bethesda
Bethesda, US (HQ)
Westmoreland Building, 6430 Rockledge Dr
Show all (1)

Spherix Financials and Metrics

Spherix Revenue

Spherix's revenue was reported to be $28 k in FY, 2018
USD

Net income (Q1, 2019)

(1.1m)

EBIT (Q1, 2019)

(713.0k)

Market capitalization (22-May-2019)

6.4m

Closing stock price (22-May-2019)

3.2

Cash (31-Mar-2019)

446.0k
Spherix's current market capitalization is $6.4 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

27.0k33.0k877.0k1.2m28.0k

Revenue growth, %

2558%

Cost of goods sold

3.0k

Gross profit

24.0k
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

1.8k3.0k2.0k72.0k177.0k314.0k327.0k311.0k314.0k

R&D expense

9.6k

Operating expense total

9.3m11.6m5.2m43.4m2.0m1.6m1.8m1.8m1.3m1.1m1.3m1.6m1.3m2.0m713.0k

EBIT

(9.3m)(11.6m)(5.2m)(43.4m)(2.0m)(1.6m)(1.6m)(1.5m)(969.0k)(777.0k)(959.0k)(1.6m)(1.3m)(2.0m)(713.0k)
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.1m142.0k134.0k197.0k17.0k

Accounts Receivable

16.2k

Inventories

Current Assets

3.3m3.9m6.3m4.3m2.9m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

2.5m7.1m5.6m87.0k157.0k494.0k392.0k303.0k210.0k733.0k233.0k63.0k178.0k109.0k446.0k

Current Assets

2.6m7.2m5.6m935.0k952.0k2.3m6.2m7.3m5.4m3.7m5.0m5.9m5.0m3.6m1.9m

PP&E

4.0k3.0k3.0k7.0k7.0k6.0k5.0k4.0k4.0k2.0k2.0k1.0k

Goodwill

1.7m1.7m1.7m1.7m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(18.0m)(51.5m)(6.5m)(3.3m)1.7m

Depreciation and Amortization

24.0k38.0k

Inventories

Accounts Payable

(158.0k)(344.0k)(261.0k)(67.0k)74.0k
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(13.8m)(19.5m)(24.7m)(47.5m)(47.1m)(49.0k)(2.1m)(2.6m)(919.0k)(2.8m)(2.3m)(1.5m)(1.9m)(3.8m)(1.1m)

Depreciation and Amortization

24.0k17.0k38.0k

Accounts Payable

501.0k(125.0k)(217.0k)(287.0k)(29.0k)(124.0k)(320.0k)52.0k(20.0k)(75.0k)110.0k150.0k12.0k(10.0k)

Cash From Operating Activities

(3.6m)(3.3m)(4.8m)(2.5m)(3.7m)(1.5m)1.8m905.0k(845.0k)(1.8m)(2.5m)(1.1m)(1.7m)(2.3m)(896.0k)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Spherix Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Hoth TherapeuticsJune 20, 2017

Spherix Online and Social Media Presence

Embed Graph

Spherix News and Updates

In Psoriasis, Use of the IL-17 Inhibitors, Novartis' Cosentyx and Eli Lilly's Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights

EXTON, Pa., April 18, 2019 /PRNewswire/ -- Spherix Global Insights has been tracking the evolution of the US psoriatic arthritis (PsA) market on a quarterly basis since 2015 via the RealTime Dynamix™: Psoriatic Arthritis (US) report series. The PsA landscape has been experiencing...

Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success

EXTON, Pa., March 25, 2019 /PRNewswire/ -- With the 2018 launches of the new class of anti-calcitonin gene-related peptide (CGRP) therapies, specifically Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality, for the prevention of migraine, the preventive treatment rate of...

Spherix Global Insights' Initial Report on the European Psoriasis Market Reveals Swift Uptake of Biosimilar Use at the Expense of AbbVie's Humira

EXTON, Pa., Feb. 19, 2019 /PRNewswire/ -- Spherix Global Insights recently published the inaugural wave of RealTime Dynamix™: Psoriasis (EU), a bi-annual tracking study that includes a mix of trended metrics, launch metrics, and variable content on the EU5 psoriasis landscape. The Q1 2019 ...

Spherix Global Insights' Recent Multiple Sclerosis Chart Audit Shows That the Current First-Line Opportunity for High-Efficacy Disease-Modifying Therapies, Including Genentech's Ocrevus and Biogen's Tysabri, May Be Limited By A Small Unfavorable Prognosis Segment Size

EXTON, Pa., Feb. 12, 2019 /PRNewswire/ -- With increasing focus on the early implementation of high-efficacy disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS), US neurologists (n=213) estimate that one-third of their MS patients who started on their...

Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Confirms the Value of First-to-Market Status for Amgen and Novartis' Aimovig as Teva's Ajovy and Eli Lilly's Emgality Strive to Differentiate From the Class Leader and Each Other

EXTON, Pa., Jan. 24, 2019 /PRNewswire/ -- In the US migraine prevention market, Amgen and Novartis' Aimovig is benefiting from its first-to-market position in the anti-calcitonin gene-related peptide (CGRP) class, which first saw the advent of competition following the September 2018...

Spherix Global Insights Reports Sun Dermatology's Ilumya Faces Challenges in A Crowded Psoriasis Market

EXTON, Pa., Dec. 5, 2018 /PRNewswire/ -- Spherix Global Insights' fourth quarter update of RealTime Dynamix™: Psoriasis (US), which includes the feedback of 100 U.S. dermatologists, reveals that Ilumya will likely face an uphill battle for adoption. Conversely, Tremfya, the first IL-23...
Show more

Spherix Frequently Asked Questions

  • When was Spherix founded?

    Spherix was founded in 1967.

  • How many employees does Spherix have?

    Spherix has 6 employees.

  • What is Spherix revenue?

    Latest Spherix annual revenue is $28 k.

  • What is Spherix revenue per employee?

    Latest Spherix revenue per employee is $4.7 k.

  • Who are Spherix competitors?

    Competitors of Spherix include Five Prime Therapeutics, Ionis Pharmaceuticals and Blue Turtle Bio.

  • Where is Spherix headquarters?

    Spherix headquarters is located at Westmoreland Building, 6430 Rockledge Dr, Bethesda.

  • Where are Spherix offices?

    Spherix has an office in Bethesda.

  • How many offices does Spherix have?

    Spherix has 1 office.